News

New data on Radium 223 presented at ASCO

Publish date: June 2, 2013
By
Mary Jo Dales

 

AT THE ASCO ANNUAL MEETING 2013

CHICAGO – Dr. Nicholas Vogelzang, investigator on the ALSYMPCA trial, discusses new data on Radium 223 (Xofigo) and new research on castration-resistant metastatic prostate cancer at the ASCO Annual Meeting 2013.

Recommended Reading

DNA changes predict prostate cancer death
MDedge Family Medicine
Obesity linked to prostatic intraepithelial neoplasia
MDedge Family Medicine
Forecast warns of urologist shortage
MDedge Family Medicine
FDA approves radiotherapy for metastatic prostate cancer
MDedge Family Medicine
Postop surveillance sufficient for stage I testicular cancer
MDedge Family Medicine
Consequences of not screening for prostate cancer prove dire
MDedge Family Medicine
New test beats PSA in predicting significant prostate Ca
MDedge Family Medicine
No higher risk of cancer after 9 years of testosterone replacement therapy
MDedge Family Medicine
Novel biomarker may measure prostate cancer aggressiveness
MDedge Family Medicine
Prostatectomy follow-up guidelines released
MDedge Family Medicine